Back to top

Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment

Kymera Therapeutics stock gained on Thursday after the company revealed quick enrollment in a clinical trial.

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Kymera Therapeutics, Inc. (KYMR)